Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.38 |
| ▸ | SAT1 | P21673 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26403289 | 0.86 | GNAI3 (0.38) | GNAI3GNAO1GNAI1PRMT6EPHX1 | |
| SCHEMBL21106031 | 0.83 | GNAI3 (0.36) | GNAI3GNAO1GNAI1PRMT6GRIN2B | |
| SCHEMBL28004439 | 0.78 | GNAI3 (0.46) | GNAI3GNAO1GNAI1PRMT6SAT1 | |
| SCHEMBL14641791 | 0.76 | GNAO1 (0.56) | GNAI3GNAO1GNAI1PRMT6SAT1 | |
| SCHEMBL15806858 | 0.75 | EPHX1 (0.46) | GNAI3GNAO1GNAI1PRMT6SAT1 | |
| SCHEMBL26282798 | 0.75 | GNAO1 (0.59) | GNAI3GNAO1GNAI1SAT1EPHX1 | |
| SCHEMBL19248417 | 0.73 | CACNA1I (0.51) | GNAI3GNAO1GNAI1PRMT6SAT1 | |
| SCHEMBL25654263 | 0.73 | GRIN2B (0.31) | GRIN2B | |
| SCHEMBL13178534 | 0.73 | NCF1 (0.48) | GNAI3GNAO1GNAI1PRMT6SAT1 | |
| SCHEMBL23945545 | 0.70 | GNAI3 (0.35) | GNAI3GNAO1GNAI1PRMT6GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | GNAI3 3162/4885GNAO1 3206/4885GNAI1 3170/4885 |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | GNAI3 3275/4885GNAO1 3982/4885GNAI1 2980/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GNAI3 1664/4885GNAO1 2977/4885GNAI1 1458/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | GNAI3 3162/4885GNAO1 3206/4885GNAI1 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.